Fascaplysin对ICR小鼠S180移植瘤的抑制作用及体内安全性的初步观察

Preliminary study on antitumor effects of Fascaplysin and safety in vivo in transplanted S180 tumor of ICR mice

目的:研究Fascaplysin对ICR小鼠移植性骨肉瘤S180瘤体的体内抑制作用。方法:急性毒性实验采用LD50数据处理程序1.01版计算LD50。皮下注射技术建立荷S180骨肉瘤的ICR小鼠动物模型,并随机分为空白对照组(注射生理盐水)、阳性对照组(CTX,30 mg.kg-1.d-1)、Fascaplysin高剂量组(20 mg.kg-1.d-1)和Fascaplysin低剂量组(5 mg.kg-1.d-1)共4组,观察相应处理10 d后各组小鼠移植瘤生长状况(抑瘤率)及瘤组织病理学形态变化。结果:阳性对照组、Fascaplysin高剂量组和Fascaplysin低剂量组的抑瘤率分别为(53±9)%、(52±10)%和(30±12)%;给药期间Fascaplysin对ICR小鼠肝、肾组织未产生明显的病理性影响,而对ICR小鼠体内S180移植瘤组织的病理性影响较为明显。结论:一定剂量的Fascaplysin对ICR小鼠S180移植性骨肉瘤生长具有较好的抑制作用,是一个有潜力的抗癌药物。

AIM：To study the inhibitory effect of Fascaplysin on the growth of transplanted S180 tumor in ICR mice. METHODS：The LD50 was counted by LD50 1.01 software for acute toxicity test.Mouse models bearing S-180 tumor were established by subcutaneous injection in ICR mice,randomly divided into 4 groups：control group（injection of saline）,positive control group（CTX,30 mg·kg-1·d-1）,high dose group（Fascaplysin,20 mg·kg-1·d-1） and low dose group（Fascaplysin,5 mg·kg-1·d-1）.The growth and histopathological changes of the tumors were observed 10 d after the corresponding treatment of all groups.RESULTS：The growth inhibition rates of positive control group,high dose group and low dose group were（53±9）%,（52±10）% and（30±12）%,respectively.Compared with the control group,there were no significant histopathological changes in liver and kidney of ICR mice during the administration of Fascaplysin,but there were significant changes in transplanted S180 tumor.CONCLUSION：A certain dose of Fascaplysin can significantly inhibit the growth of transplanted S180 tumor in ICR mice.It is a potential antitumor lead compound.